Cargando…

Neuropeptide Treatment with Cerebrolysin Enhances the Survival of Grafted Neural Stem Cell in an α-Synuclein Transgenic Model of Parkinson’s Disease

Neuronal stem cell (NSC) grafts have been investigated as a potential neuro-restorative therapy in Parkinson’s disease (PD) but their use is compromised by the death of grafted cells. We investigated the use of Cerebrolysin (CBL), a neurotrophic peptide mixture, as an adjunct to NSC therapy in the α...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rockenstein, Edward, Desplats, Paula, Ubhi, Kiren, Mante, Michael, Florio, Jazmin, Adame, Anthony, Winter, Stefan, Brandstaetter, Hemma, Meier, Dieter, Moessler, Herbert, Masliah, Eliezer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Libertas Academica 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938121/ https://www.ncbi.nlm.nih.gov/pubmed/27429559 http://dx.doi.org/10.4137/JEN.S25521

Ejemplares similares

Neuroprotective effects of Cerebrolysin in triple repeat Tau transgenic model of Pick’s disease and fronto-temporal tauopathies
por: Rockenstein, Edward, et al.
Publicado: (2015)

Cerebrolysin™ efficacy in a transgenic model of tauopathy: role in regulation of mitochondrial structure
por: Rockenstein, Edward, et al.
Publicado: (2014)

Role of Alterations in Protein Kinase p38γ in the Pathogenesis of the Synaptic Pathology in Dementia With Lewy Bodies and α-Synuclein Transgenic Models
por: Iba, Michiyo, et al.
Publicado: (2020)

Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy
por: Valera, Elvira, et al.
Publicado: (2017)

Brain-derived exosomes from dementia with Lewy bodies propagate α-synuclein pathology
por: Ngolab, Jennifer, et al.
Publicado: (2017)

Correction to: Brain-derived exosomes from dementia with Lewy bodies propagate α-synuclein pathology
por: Ngolab, Jennifer, et al.
Publicado: (2020)

A Novel Triple Repeat Mutant Tau Transgenic Model That Mimics Aspects of Pick’s Disease and Fronto-Temporal Tauopathies
por: Rockenstein, Edward, et al.
Publicado: (2015)

Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease
por: Masliah, Eliezer, et al.
Publicado: (2011)

α‐synuclein conformational antibodies fused to penetratin are effective in models of Lewy body disease
por: Spencer, Brian, et al.
Publicado: (2016)

Neuroprotective effects of the immunomodulatory drug FK506 in a model of HIV1-gp120 neurotoxicity
por: Fields, Jerel A., et al.
Publicado: (2016)

Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5 – implications for dementia with Lewy bodies
por: Overk, Cassia R, et al.
Publicado: (2014)

MicroRNA-101 Modulates Autophagy and Oligodendroglial Alpha-Synuclein Accumulation in Multiple System Atrophy
por: Valera, Elvira, et al.
Publicado: (2017)

Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy
por: Spencer, Brian, et al.
Publicado: (2017)

TOM40 Mediates Mitochondrial Dysfunction Induced by α-Synuclein Accumulation in Parkinson’s Disease
por: Bender, Andreas, et al.
Publicado: (2013)

Longitudinal live imaging of retinal α-synuclein::GFP deposits in a transgenic mouse model of Parkinson’s Disease/Dementia with Lewy Bodies
por: Price, Diana L., et al.
Publicado: (2016)

Hypoestoxide reduces neuroinflammation and α-synuclein accumulation in a mouse model of Parkinson’s disease
por: Kim, Changyoun, et al.
Publicado: (2015)

Effects of cerebrolysin on nerve growth factor system in the aging rat brain
por: Stepanichev, Mikhail, et al.
Publicado: (2017)

Alterations in mGluR5 Expression and Signaling in Lewy Body Disease and in Transgenic Models of Alpha-Synucleinopathy – Implications for Excitotoxicity
por: Price, Diana L., et al.
Publicado: (2010)

Preserved functional autonomic phenotype in adult mice overexpressing moderate levels of human alpha‐synuclein in oligodendrocytes
por: Tank, Jens, et al.
Publicado: (2014)

Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson’s disease
por: Valera, Elvira, et al.
Publicado: (2015)

Differential Effects of UCHL1 Modulation on Alpha-Synuclein in PD-Like Models of Alpha-Synucleinopathy
por: Cartier, Anna E., et al.
Publicado: (2012)

Synergistic Increase of Serum BDNF in Alzheimer Patients Treated with Cerebrolysin and Donepezil: Association with Cognitive Improvement in ApoE4 Cases
por: Alvarez, X. Anton, et al.
Publicado: (2016)

The Temporal Expression Pattern of Alpha-Synuclein Modulates Olfactory Neurogenesis in Transgenic Mice
por: Schreglmann, Sebastian R., et al.
Publicado: (2015)

ESCRT-mediated Uptake and Degradation of Brain-targeted α-synuclein Single Chain Antibody Attenuates Neuronal Degeneration In Vivo
por: Spencer, Brian, et al.
Publicado: (2014)

Effects of Novel Calpain Inhibitors in Transgenic Animal Model of Parkinson’s disease/dementia with Lewy bodies
por: Hassen, Getaw Worku, et al.
Publicado: (2018)

A brain-targeted, modified neurosin (kallikrein-6) reduces α-synuclein accumulation in a mouse model of multiple system atrophy
por: Spencer, Brian, et al.
Publicado: (2015)

Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating α-synuclein transmission and neuroinflammation
por: Kim, Changyoun, et al.
Publicado: (2018)

Combined exposure to Maneb and Paraquat alters transcriptional regulation of neurogenesis-related genes in mice models of Parkinson’s disease
por: Desplats, Paula, et al.
Publicado: (2012)

Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy
por: Mandler, Markus, et al.
Publicado: (2015)

Efficacy and safety of Cerebrolysin in patients with hemorrhagic stroke
por: Bajenaru, O, et al.
Publicado: (2010)

Effects of innate immune receptor stimulation on extracellular α-synuclein uptake and degradation by brain resident cells
por: Kim, Changyoun, et al.
Publicado: (2021)

Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial
por: Muresanu, Dafin F., et al.
Publicado: (2016)

APP transgenic modeling of Alzheimer’s disease: mechanisms of neurodegeneration and aberrant neurogenesis
por: Crews, Leslie, et al.
Publicado: (2009)

Safety and efficacy of Cerebrolysin in motor function recovery after stroke: a meta-analysis of the CARS trials
por: Guekht, Alla, et al.
Publicado: (2017)

Time course and progression of wild type α-Synuclein accumulation in a transgenic mouse model
por: Amschl, David, et al.
Publicado: (2013)

Oligomer-prone E57K-mutant alpha-synuclein exacerbates integration deficit of adult hippocampal newborn neurons in transgenic mice
por: Regensburger, Martin, et al.
Publicado: (2017)

Selective Molecular Alterations in the Autophagy Pathway in Patients with Lewy Body Disease and in Models of α-Synucleinopathy
por: Crews, Leslie, et al.
Publicado: (2010)

Neuregulin 1 improves cognitive deficits and neuropathology in an Alzheimer’s disease model
por: Xu, Jiqing, et al.
Publicado: (2016)

Synuclein impairs trafficking and signaling of BDNF in a mouse model of Parkinson’s disease
por: Fang, Fang, et al.
Publicado: (2017)

Serum VEGF Predicts Clinical Improvement Induced by Cerebrolysin Plus Donepezil in Patients With Advanced Alzheimer’s Disease
por: Alvarez, X Anton, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_797otd1evgbe71mcm97fnnnhg0